FDA Approves Zetonna

FRIDAY, January 20, 2012 - The U.S. Food and Drug Administration today approved Zetonna (ciclesonide) nasal aerosol to treat the symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Ciclesonide is a corticosteroid first approved for nasal use as Omnaris in October 2006. Zetonna nasal aerosol is formulated with a hydrofluoroalkane (HFA) propellant in a delivery system designed to dispense ciclesonide medication as a fine dry mist in a small volume (50 mcL) to a patient's nose, which may be able to reduce sensory effects such as back-of- the-throat run-off and run-out out of the nose that can occur with aqueous-based corticosteroids.
A large phase III clinical study investigated 74 mcg or 148 mcg doses of ciclesonide nasal aerosol once-daily in 1,111 patients, 12 years of age and older with perennial allergic rhinitis (PAR). This 26 week, double-blind, randomized study demonstrated  statistically significant improvements in nasal symptoms in patients with PAR compared to placebo, after the first six weeks of double-blind treatment, for both the 74 mcg and 148 mcg doses. Results from the full 26 week, double-blind treatment period demonstrated tolerability of both the 74 mcg and 148 mcg doses of ciclesonide nasal aerosol compared to placebo.
The most common adverse reactions (≥2% incidence) included nasal discomfort, headache and epistaxis. Zetonna Nasal Aerosol may cause more serious adverse reactions which include nasal septal perforation and nasal ulceration. Zetonna Nasal Aerosol should not be sprayed directly onto the nasal septum, and patients who have experienced recent nasal septal perforation, nasal erosion, nasal ulcers, nasal surgery, or nasal trauma should not use Zetonna until healing has occurred.
Patients should be advised that glaucoma and cataracts are associated with nasal and inhaled corticosteroid use and should inform their health care provider if a change in vision is noted while using Zetonna Nasal Aerosol.
Patients should call their doctor if they are exposed to chickenpox or measles; and existing tuberculosis, fungal, bacterial, viral or parasitic infections, or ocular herpes simplex infections may become worse in patients using Zetonna.
Zetonna Nasal Aerosol should be used on a regular, once daily basis, with maximum benefit usually achieved within 1 to 2 weeks after initiation of dosing.

Comments

Post a Comment

Popular posts from this blog

Pharmacy Examining Board of Canada Questions & Answers

Image
Overview Q1 What is the Pharmacy Examining Board of Canada? The Pharmacy Examining Board of Canada ( PEBC ) is the national certification body for the pharmacy profession in Canada. PEBC is a non-profit organization with more than 40 years of experience in assessing the qualifications and competence of candidates for licensing by pharmacy provincial regulatory authorities. Established by Special Act of Parliament on December 21,1963, PEBC functions as an arms-length national examining board for pharmacists seeking entry-to-practice licensure in Canada. Q2 What is the purpose of the PEBC?
Read more

Paints in pharmacy| glycerin borax preparation is the first

Image
(1) GLYCERIN BORAX PREPARATION 13% Borax 13gm Glycerin to 100ml Levigate the borax powder into a suitable amount of glycerin then complete to 100ml.  Glycerin of borax uses: Used as a soothing agent in mouth ulcers also used in nipple fissures. (2) GLYCERIN TANNIC ACID PAINT 15% Tannic acid 15gm Glycerin to 100 ml Astringent in spongy gum and sore throat and applied to eyelid in trachoma. 1g of Na-citrate can be added (3) Glycerin borax and Tr.benzoin SOLUTION Glycerin borax 20 ml Tr.benzoin 10 ml Used in nipple fissure (4) DENTAL GLYCERIN ( zinc chloride) ZnCL2 1gm Glycerin 1.6ml H2O 0.5ml Alcohol 1.5ml used for de-sensation for exposed dentin (5) GENTIAN VIOLET PAINT (Rosaniline dyes) Gentian violet 1 gm Alcohol 70% 100 ml Used as antiseptic and in moniliasis. 2g of G. V can be used with 100 ml of glycerin borax in breast fissures. (6) ALCOHOLIC MERCUROCHROME PAINT Mercurochrome 2gm Alcohol 70% to 100 ml (7) Mercurochrom...
Read more

Facts about SOVALDI Therapy

Image
SOVALDI  It is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%. Here is some facts about SOVALDI that pharmacist must know: Active constituent of SOVALDI is sofosbuvir 400 mg. SOVALDI is effective against the four genotypes of HIV infection, including patients with HCC that in waiting list for liver transplantation, and those carrying HIV-1/HCV co-infection. SOVALDI not recommended using alone for Chronic Hepatitis C patients. The dose of SOVALDI is 400 mg once daily, to be taken regardless of food. Genotype-1 HCV treated for 12 weeks with SOVALDI +Peginterferon alfa +ribavirin, and for 24 weeks if used without peginterferon alfa. Genotype-2 HCV treated for 12 weeks with SOVALDI +ribavirin. Genotype-3 HCV treated for 24 weeks with SOVALDI +ribavirin. Genotype-4 treated for 12 weeks with SOVALDI +Peginterferon a...
Read more